New York, New York-- (Newsfile Corp. - February 7, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public ...

Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the ...

In another sign that the biotech IPO market is picking up, cell therapy specialist Kyverna has filed to raise roughly $211 million from the sale of around 11 million shares at between $17 and $19 ...

Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ ...

Allogeneic CAR-T therapies, highlighted by Allogene, Kyverna, and Caribou, are emerging as promising alternatives. These “off-the-shelf” solutions eliminate the need for apheresis, offer ...

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. The global market for autoimmune disease therapeutics is forecast to generate $185 billion ...